CSL Ltd (ASX: CSL) will report its 2026 half-year financial results this morning. The update comes as the company prepares for a change in senior leadership.
Just after market close on Tuesday, CSL confirmed that chief executive officer and managing director Dr Paul McKenzie will retire. Gordon Naylor has been appointed interim CEO and managing director, effective from 11 February 2026.
The timing places leadership succession firmly in focus as investors await the company's earnings update and outlook commentary.
CSL shares were volatile during Tuesday's session. The stock was trading up around 2.2% at around $184.02 in late afternoon trade before reversing direction to finish the day down 4.98% at $171.39.
Image source: Getty Images
Leadership change after 3 years as CEO
Dr McKenzie served as CSL's CEO and managing director since late 2022. His tenure covered a challenging period marked by shifting demand conditions, cost pressures and operational adjustments across parts of the group.
CSL chair Brian McNamee said the board determined it was the right time for new leadership to continue driving the company's strategic transformation. He also acknowledged Dr McKenzie's contribution during a period that included post-pandemic operational stabilisation and ongoing investment in research and development.
Incoming interim CEO Gordon Naylor is a long-time CSL executive and current non-executive director, with more than 3 decades of experience at the company. His background includes senior leadership roles across plasma therapies and vaccines, as well as involvement in major acquisitions and infrastructure expansion.
The board said Naylor will have full authority during the interim period while a search for a permanent CEO takes place.
Half-year results due before market open
CSL is scheduled to release its half-year financial results for the six months ended 31 December 2025 before the market opens today.
An investor and analyst briefing will follow at 10:00am AEDT via webcast.
The result is also expected to include the declaration of an interim dividend. Historically, the interim dividend is paid in April, with the ex-dividend date typically falling in early March.
What investors will be watching
While the leadership change is notable, attention will remain firmly on the numbers and forward guidance.
Investors will be focused on revenue performance across CSL's plasma and specialty therapies businesses, margins, currency impacts and commentary around second-half trading conditions.
Any update to full-year guidance is likely to be closely watched, particularly given recent share price weakness.
With CSL shares well below previous highs and sentiment still fragile, the earnings update comes at an important time.
